Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Anemia drugs
Biotech
J&J finds another path for Momenta drug in rare fetal disorder
A topline phase 2 readout for nipocalimab in a fetal disorder is a reminder that the drug could have a far broader reach than myasthenia gravis.
James Waldron
Feb 6, 2023 10:20am
GSK pulls off clean sweep of endpoint hits in anemia phase 3
Nov 8, 2021 7:25am
GSK files for Japanese approval of oral anemia drug
Aug 21, 2019 8:54am
FibroGen’s renal anemia drug closer to EU filing
Sep 20, 2018 9:48am
Prolific dealmakers Akebia and Vifor pen anemia drug pact
May 16, 2017 5:42am
Akebia, Otsuka pen $865M expansion to anemia pill pact
Apr 26, 2017 4:48am
